| Bioactivity | Derazantinib (ARQ-087) dihydrochloride is an ATP competitive and orally activeFGFR inhibitor (IC50s: 1.8 nM for FGFR2, 4.5 nM for FGFR1 and 3). Derazantinib dihydrochloride inhibits FGFR phosphorylation. Derazantinib dihydrochloride inhibits tumor growth in multiple xenograft models[1][2]. |
| Target | 1.8 nM for FGFR2, 4.5 nM for FGFR1 and 3 nM |
| Name | Derazantinib dihydrochloride |
| CAS | 1821329-75-2 |
| Formula | C29H31Cl2FN4O |
| Molar Mass | 541.49 |
| Transport | Room temperature in continental US; may vary elsewhere. |
| Storage | Please store the product under the recommended conditions in the Certificate of Analysis. |
| Reference | [1]. Hall TG, et al. Preclinical Activity of ARQ-087, a Novel Inhibitor Targeting FGFR Dysregulation. PLoS One. 2016 Sep 14;11(9):e0162594. [2]. Balek L, et al. ARQ-087 inhibits FGFR signaling and rescues aberrant cell proliferation and differentiation in experimental models of craniosynostoses and chondrodysplasias caused by activating mutations in FGFR1, FGFR2 and FGFR3. Bone. 2017 Dec;105:57-66. |
Derazantinib dihydrochloride
CAS: 1821329-75-2 F: C29H31Cl2FN4O W: 541.49
Derazantinib (ARQ-087) dihydrochloride is an ATP competitive and orally activeFGFR inhibitor (IC50s: 1.8 nM for FGFR2, 4
Data collection：peptidedb@qq.com
This product is for research use only, not for human use. We do not sell to patients.